Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Tandem Diabetes Care

Biotech & Life Sciences · San Diego, United States · Founded 2006 · IPO 2013 Unicorn

Medical devices for the treatment of diabetes offering diabetic insulin pumps for adults and children

Valuation
$1.49B
Market cap · May/2026
Revenue
$1.01B
Latest reported FY
EBITDA
$58M
Latest reported FY

Investors

4 investors on Tandem Diabetes Care's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 4 investors entered at this stage
Domain Associates
TPG Biotech
Delphi Ventures
TPG

Global footprint

Where Tandem Diabetes Care has talent and traffic

AI talent share
0.3% of workforce is AI talent
(6 of 2,175 staff)
Core AI00%
Other AI60.28%
Non-AI workforce2,16999.72%
Workforce by country
13 countries with
team presence
🇺🇸 United States95.2%
🇨🇦 Canada2.3%
🇨🇭 Switzerland1.4%
🇬🇧 United Kingdom0.2%
🇫🇷 France0.2%
Top 5 of 13 shown
Web traffic by country
390K monthly visits
across markets
🇺🇸 United States66.3%
🇨🇦 Canada10.6%
🇬🇧 United Kingdom3.3%
🇿🇦 South Africa2%
🇮🇹 Italy1.9%
Top 5 markets shown

Patent intelligence

$109M patent portfolio · 164 active families

Estimated portfolio value
$109M
7.3% of market cap · 4.6× smaller than top peer Insulet ($502M)
164 active patent families
Where Tandem Diabetes Care innovates Biomedical engineeringInsulinDrug deliveryPancreatic hormonePharmaceutical drug

Where Tandem Diabetes Care concentrates vs peers

Each axis is a top-10 topic across Tandem Diabetes Care and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Tandem Diabetes Care's 3 investments and acquisitions.

Every disclosed deal where Tandem Diabetes Care appeared as a backer or acquirer, 2021–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Tandem Diabetes Care's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Tandem Diabetes Care deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Tandem Diabetes Care's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Tandem Diabetes Care

        An AI-synthesized read of the highest-engagement posts about Tandem Diabetes Care on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Tandem Diabetes Care on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.